Below are the most recent publications written about "Receptors, Notch" by people in Profiles.
-
Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, Chu Q. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022 03 24; 7(1):95.
-
Chen ELY, Lee CR, Thompson PK, Wiest DL, Anderson MK, Z??iga-Pfl?cker JC. Ontogenic timing, T?cell receptor signal strength, and Notch signaling direct ?d T?cell functional differentiation in?vivo. Cell Rep. 2021 06 08; 35(10):109227.
-
Zarin P, In TS, Chen EL, Singh J, Wong GW, Mohtashami M, Wiest DL, Anderson MK, Z??iga-Pfl?cker JC. Integration of T-cell receptor, Notch and cytokine signals programs mouse ?d T-cell effector differentiation. Immunol Cell Biol. 2018 10; 96(9):994-1007.
-
Onoufriadis A, Hsu CK, Ainali C, Ung CY, Rashidghamat E, Yang HS, Huang HY, Niazi U, Tziotzios C, Yang JC, Nuamah R, Tang MJ, Saxena A, de Rinaldis E, McGrath JA. Time Series Integrative Analysis of RNA Sequencing?and MicroRNA Expression Data Reveals?Key Biologic Wound Healing Pathways?in?Keloid-Prone Individuals. J Invest Dermatol. 2018 12; 138(12):2690-2693.
-
Juskeviciute E, Dippold RP, Antony AN, Swarup A, Vadigepalli R, Hoek JB. Inhibition of miR-21 rescues liver regeneration after partial hepatectomy in ethanol-fed rats. Am J Physiol Gastrointest Liver Physiol. 2016 Nov 01; 311(5):G794-G806.
-
Briot A, Jaroszewicz A, Warren CM, Lu J, Touma M, Rudat C, Hofmann JJ, Airik R, Weinmaster G, Lyons K, Wang Y, Kispert A, Pellegrini M, Iruela-Arispe ML. Repression of Sox9 by Jag1 is continuously required to suppress the default chondrogenic fate of vascular smooth muscle cells. Dev Cell. 2014 Dec 22; 31(6):707-21.
-
Viswanathan V, Fields J, Boman BM. The miRNA23b-regulated signaling network as a key to cancer development--implications for translational research and therapeutics. J Mol Med (Berl). 2014 Nov; 92(11):1129-38.
-
Illa-Bochaca I, Ouyang H, Tang J, Sebastiano C, Mao JH, Costes SV, Demaria S, Barcellos-Hoff MH. Densely ionizing radiation acts via the microenvironment to promote aggressive Trp53-null mammary carcinomas. Cancer Res. 2014 Dec 01; 74(23):7137-48.
-
Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013 Mar 15; 19(6):1512-24.
-
Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012 Sep 11; 22(3):373-88.